Literature DB >> 28820074

Exploring the Cardio-metabolic Relevance of T-cadherin: A Pleiotropic Adiponectin Receptor.

Jaime L Clark1, Carla G Taylor1, Peter Zahradka1.   

Abstract

BACKGROUND AND
OBJECTIVE: T-cadherin is a unique member of the cadherin family and is primarily expressed in the cardiovascular system. T-cadherin has not been abundantly studied, but the studies conducted to date have explored the impact of this protein on health and the function of organs involved in metabolic regulation.
METHODS: This article examines the recent knowledge of the ligand partners for T-cadherin and the potential contribution(s) of T-cadherin to cardio-metabolic function. RESULT AND DISCUSSION: One significant role for T-cadherin is its ability to bind high molecular weight adiponectin in cardiovascular tissue, thereby mediating the cardio-protective benefits of adiponectin. It also has the ability to bind low-density lipoprotein via its glycosylphosphatidylinositol anchor; however, the exact physiological consequence of this ligand-receptor relationship is not known. T-cadherin appears to affect multiple conditions of cardio-metabolic disease, including atherosclerosis and insulin resistance. Research into T-cadherin has suggested that it may be useful as a diagnostic marker for the early stages of cardiovascular disease. However, with regard to insulin, T-cadherin is necessary for pancreatic insulin secretion, but overexpression of T-cadherin on vascular cells may promote endothelial insulin resistance.
CONCLUSION: This review provides evidence that T-cadherin has an influential role on key cardiometabolic molecules and warrants further investigation. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  T-cadherin; adiponectin; atherosclerosis; insulin; insulin resistance; low-density lipoprotein

Mesh:

Substances:

Year:  2017        PMID: 28820074     DOI: 10.2174/1871530317666170818120224

Source DB:  PubMed          Journal:  Endocr Metab Immune Disord Drug Targets        ISSN: 1871-5303            Impact factor:   2.895


  5 in total

Review 1.  Adiponectin Signaling Pathways in Liver Diseases.

Authors:  Tania Gamberi; Francesca Magherini; Alessandra Modesti; Tania Fiaschi
Journal:  Biomedicines       Date:  2018-05-07

Review 2.  Adiponectin in Chronic Kidney Disease.

Authors:  Jarosław Przybyciński; Violetta Dziedziejko; Kamila Puchałowicz; Leszek Domański; Andrzej Pawlik
Journal:  Int J Mol Sci       Date:  2020-12-09       Impact factor: 5.923

3.  Integrated microRNA and mRNA Expression Profiling Identifies Novel Targets and Networks Associated with Ebstein's Anomaly.

Authors:  Masood Abu-Halima; Viktoria Wagner; Lea Simone Becker; Basim M Ayesh; Mohammed Abd El-Rahman; Ulrike Fischer; Eckart Meese; Hashim Abdul-Khaliq
Journal:  Cells       Date:  2021-04-30       Impact factor: 6.600

4.  Adiponectin protects obesity-related glomerulopathy by inhibiting ROS/NF-κB/NLRP3 inflammation pathway.

Authors:  Xiaohong Xu; Xiaolin Huang; Liexiang Zhang; Xiaoli Huang; Zihan Qin; Fei Hua
Journal:  BMC Nephrol       Date:  2021-06-10       Impact factor: 2.388

Review 5.  Rebelling against the (Insulin) Resistance: A Review of the Proposed Insulin-Sensitizing Actions of Soybeans, Chickpeas, and Their Bioactive Compounds.

Authors:  Jaime L Clark; Carla G Taylor; Peter Zahradka
Journal:  Nutrients       Date:  2018-03-30       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.